- Home
- SITC vs FHTX Comparison
SITC vs FHTX Comparison
Compare SITC & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SITC | FHTX |
|---|---|---|
| Founded | 1965 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medicinal Chemicals and Botanical Products |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 154.8M | 173.4M |
| IPO Year | 1994 | 2020 |
Fundamental Metrics
Financial Performance| Metric | SITC | FHTX |
|---|---|---|
| Price | $3.44 | $1.86 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $4.17 |
| AVG Volume (30 Days) | ★ 1.4M | 1.2M |
| Earning Date | 11-04-2026 | 11-04-2026 |
| Dividend Yield | ★ 99.67% | N/A |
| EPS Growth | N/A | ★ 25.32 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $123,649,000.00 | $30,909,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $15.98 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 36.75 |
| 52 Week Low | $2.80 | $1.79 |
| 52 Week High | $8.95 | $7.61 |
Technical Indicators
Market Signals| Indicator | SITC | FHTX |
|---|---|---|
| Relative Strength Index (RSI) | 65.16 | 16.35 |
| Support Level | $2.86 | $1.79 |
| Resistance Level | $3.55 | $5.35 |
| Average True Range (ATR) | 0.15 | 0.24 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 75.18 | 2.07 |
Price Performance
Historical ComparisonAbout SITC SITE Centers Corp.
SITE Centers Corp is a self-administered and self-managed REIT that operates as a fully integrated real estate company. The company is engaged in the business of owning, leasing, acquiring, redeveloping, developing, and managing shopping centers.
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.